| Unique ID issued by UMIN | UMIN000058413 |
|---|---|
| Receipt number | R000066783 |
| Scientific Title | Clinical Efficacy of PRP Therapy for the Face: A Self-Controlled Prospective Evaluation |
| Date of disclosure of the study information | 2025/07/09 |
| Last modified on | 2025/10/17 12:05:40 |
Clinical Efficacy of PRP Therapy for the Face: A Self-Controlled Prospective Evaluation
Clinical Efficacy of PRP Therapy for the Face: A Self-Controlled Prospective Evaluation
Clinical Efficacy of PRP Therapy for the Face: A Self-Controlled Prospective Evaluation
Clinical Efficacy of PRP Therapy for the Face: A Self-Controlled Prospective Evaluation
| Japan |
Skin tissue that has atrophied or changed due to aging, trauma, congenital etc.
| Dermatology | Aesthetic surgery | Adult |
Others
NO
This study will use a prospective survey based on patient data to examine the effectiveness of PRP treatment on skin tissue that has atrophied or been deformed due to aging, trauma, congenital conditions, etc.
Efficacy
Photographs and a patient satisfaction survey will be conducted at 1 month, 3 months, and 6 months after the start of treatment.
At 2 weeks and 1 month following the start of treatment, image analysis will be conducted with the neoVoir imaging system.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
| Medicine |
PRP is prepared using the patient's own blood as the source material.
The prepared PRP is then administered to the patient's face.
Injection is performed on both the right and left sides of the face as follows:
Left side: PRP
Right side: Normal saline
The injections are performed using a mesotherapy device, with the target depth being the dermal layer.
The volume of PRP to be administered will be 5 mL.
| 18 | years-old | <= |
| Not applicable |
Male and Female
Individuals who meet all of the following criteria
Have clear tissue deformity or atrophy due to congenital conditions, trauma, or aging
Are expected to benefit from this treatment
Wish to receive the treatment and have been deemed suitable for it by a physician
Are able to attend outpatient visits
adults
Have provided written informed consent for this treatment
Have a clearly apparent infection in the area surrounding the injection site
Have a predisposition to keloid formation
Have an insufficient understanding of this treatment
Lack the capacity to make an informed decision regarding this treatment
Do not wish to receive this treatment or are unable to provide informed consent
Are deemed inappropriate for the treatment by the physician, such as those with malignant tumors, infectious tumors, infectious diseases, or inflammatory diseases
10
| 1st name | Hiroo |
| Middle name | |
| Last name | Teranishi |
Tokyo Chuo Beauty Clinic (TCB), BS Clinic, Umeda Osaka Ekimae Branch
Director
5300057
3rd Floor, K's Square Building, 2-8-15 Sonezaki, Kita-ku, Osaka-city, Osaka, Japan
06-6147-2581
umeda.office@tcb.or.jp
| 1st name | Masashi |
| Middle name | |
| Last name | Umeda |
Tokyo Chuo Beauty Clinic (TCB), BS Clinic, Umeda Osaka Ekimae Branch
Tokyo Chuo Beauty Clinic (TCB), BS Clinic, Umeda Osaka Ekimae Branch
5300057
3rd Floor, K's Square Building, 2-8-15 Sonezaki, Kita-ku, Osaka-city, Osaka, Japan
06-6147-2581
dr.umeda.masashi@tcb.or.jp
Tokyo Chuo Beauty Clinic (TCB), BS Clinic, Umeda Osaka Ekimae Branch
None
Self funding
TCB Academic Committee and IRB
3rd Floor, K's Square Building, 2-8-15 Sonezaki, Kita-ku, Osaka-city, Osaka, Japan
06-6147-2581
irb@tcb.or.jp
NO
| 2025 | Year | 07 | Month | 09 | Day |
Unpublished
Enrolling by invitation
| 2025 | Year | 04 | Month | 01 | Day |
| 2025 | Year | 03 | Month | 29 | Day |
| 2025 | Year | 04 | Month | 15 | Day |
| 2025 | Year | 10 | Month | 31 | Day |
| 2025 | Year | 07 | Month | 09 | Day |
| 2025 | Year | 10 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066783